Research programme: andrology therapeutics - CamurusAlternative Names: CAM 2035
Latest Information Update: 14 Jan 2014
At a glance
- Originator Camurus
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 14 Jan 2014 Discontinued - Preclinical for Undefined indication in Sweden (unspecified route)
- 07 Aug 2007 Preclinical trials in Undefined indication in Sweden (unspecified route)